Therapeutics News

Recombinant deoxyribonuclease eye drops show potential in reducing both the signs and severity of dry eye in patients with severe tear-deficient dry eye disease, according to a study published in Translational Vision Science & Technology.

Researchers have shown that a novel eye drop can be used as a method of sustained delivery of antifibrotic drugs in patients with fibrosis associated with bacterial keratitis, according to a study published in npj Regenerative Medicine.

A new hypotensive agent that could potentially enrich the armamentarium of glaucoma medications showed efficacy and safety in phase 2 trials.

In a large 3-year trial, selective laser trabeculoplasty showed better control of IOP and better cost-effectiveness than eye drops as a first-line treatment for glaucoma and ocular hypertension. According to the authors, these findings suggest that selective laser trabeculoplasty (SLT) should be offered as a first-line treatment, supporting a change in clinical practice.

“As we are able to diagnose glaucoma earlier and earlier and have a better understanding of the disease, it will help to determine the most appropriate therapy for the individual patient, whether that is drops, sustained release or surgical intervention,” private practitioner Chris Wroten, OD, told Primary Care Optometry News.

Much has been written about screening for hydroxychloroquine toxicity.

Nocturnal IOP-related fluctuations are significantly more pronounced in medically treated than in surgically treated glaucoma, according to a study.

Novartis announced that its spinoff of Alcon is expected to be completed April 9.

A study published in Cornea showed that the ocular antihistamine ketotifen was effectively delivered via a contact lens also designed for visual correction.

Children 3 to 10 years old with intermittent exotropia are not likely to progress to constant exotropia and may improve spontaneously over 3 years, according to a study.